ClinicalTrials.gg
RecruitingNCT06381362IGOMIPSUpdated Apr 24, 2024

Italian Registry of Minimally Invasive Pancreatic Surgery

An observational study in Pancreatic Surgery, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Associazione Italiana per lo Studio del Pancreas · Observational

How we know

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,300
Ages
18 Years and older
Sex
All
01

Study summary

Assess the prevalence of minimally invasive pancreatic surgery in the country and its outcomes

Read the detailed description

Since 1994, when the first pancreatectomy surgeries, distal and proximal, conducted minimally invasively, were published, efforts have been made to understand the value of this approach in the context of a surgery as complex and burdened with specific complications as pancreatic surgery. The adoption of such an approach with regard to pancreatic surgery has been less rapid and parceled out than in other surgical fields and not supported by a large body of scientific publications. However, worldwide, referral centers for pancreatic surgery routinely use the minimally invasive approach in selected cases, and its diffusion has recently shown a marked increase. Even in Italy, a recent survey promoted by some of the major surgical societies showed a fair diffusion of the use of the minimally invasive approach in pancreatic surgery but with extremely variable ways and uses in the different territorial realities with evident and potentially risky paradoxes. Monitoring the diffusion of minimally invasive pancreatic surgery, the methods of application and the results of this approach has become of primary importance and for this reason the foundation of a national registry has been proposed by several scientific surgical societies.

This study aims to investigate what is the real diffusion of minimally invasive techniques in Italy and what postoperative outcomes the adoption of this approach generates.

02

Conditions studied

  • Pancreatic Surgery
03

In context

Lead sponsor

Associazione Italiana per lo Studio del Pancreas is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

The study will involve all patients undergoing at participating centers a pancreatic surgery performed by minimally invasive technique (e.g., laparoscopic, robotic), over the age of 18 years, capable of expressing consent to the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years;
  • Underwent minimally invasive pancreatic surgery

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman
  • Minor or unable to give
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,300 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • ProcedureMinimally invasive pancreatic surgery

    Minimally invasive pancreatic surgery

06

What researchers measure

Primary outcomes

  1. Postoperative short-term outcomes

    any complication graded according to Clavien-Dindo classification

    Time frame: 90 days

  2. Long-term oncological outcomes

    Disease recurrence or disease related death

    Time frame: 2 years

Secondary outcomes

  1. Rate of cases that after a minimally invasive approach had to be converted to and open approach

    Intraoperative conversion to open surgery for any reason

    Time frame: Intraoperative

  2. Surgeon learning curve

    Variation of surgical time according to the registered case-load as operating surgeon and first assistant

    Time frame: Intraoperative

  3. Surgeon learning curve

    Variation of intraoperative blood-loss according to the registered case-load as operating surgeon and first assistant

    Time frame: Intraoperative

  4. Surgeon learning curve

    Variation of intraoperative complications rate according to the registered case-load as operating surgeon and first assistant

    Time frame: Intraoperative

  5. Surgeon learning curve

    Variation of conversion rate according to the registered case-load as operating surgeon and first assistant

    Time frame: Intraoperative

07

Study locations

1 of 1 sites recruiting
  • Giovanni Capretti
    Milan, Italy
    Recruiting
    • Giovanni Capretti, Dr. · Contactgiovanni.capretti@hunimed.eu · +390282247646
    • Alessandro Zerbi, Prof. · Principal investigator
    • Giovanni Capretti, Dr. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2019 (actual). Primary completion is estimated for Feb 2029, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Apr 24, 2024
StartActual
Feb 28, 2019
Primary completionEst.
Feb 28, 2029
CompletionEst.
Feb 28, 2029
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06381362
Lead sponsor
Associazione Italiana per lo Studio del Pancreas
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Feb 28, 2019
Primary completion
Feb 28, 2029 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Apr 24, 2024

Study contacts

Alessandro Zerbi, Prof.
Contact
alessandro.zerbi@hunimed.eu
+390282245941
Alessandro Zerbi, Prof.
principal investigator · Humanitas Research Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion